FinTrust Capital Advisors LLC grew its position in NeoGenomics, Inc. (NASDAQ:NEO) by 27.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,270 shares of the medical research company’s stock after acquiring an additional 270 shares during the period. FinTrust Capital Advisors LLC’s holdings in NeoGenomics were worth $47,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in NEO. Cullen Frost Bankers Inc. bought a new position in shares of NeoGenomics in the 2nd quarter valued at about $31,000. Valeo Financial Advisors LLC grew its position in shares of NeoGenomics by 150.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 1,000 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 600 shares during the period. Fiduciary Planning LLC acquired a new stake in shares of NeoGenomics during the 3rd quarter worth about $41,000. Flagship Harbor Advisors LLC lifted its stake in shares of NeoGenomics by 48.0% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 1,310 shares of the medical research company’s stock worth $48,000 after buying an additional 425 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of NeoGenomics during the 3rd quarter worth about $55,000. 91.67% of the stock is owned by institutional investors.
A number of analysts have recently issued reports on NEO shares. SVB Leerink raised their target price on shares of NeoGenomics from $47.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday. Craig Hallum raised their target price on shares of NeoGenomics from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. ValuEngine cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, November 2nd. Needham & Company LLC raised their target price on shares of NeoGenomics from $39.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Finally, Zacks Investment Research cut shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $40.96.
Shares of NeoGenomics stock opened at $44.77 on Friday. NeoGenomics, Inc. has a twelve month low of $20.47 and a twelve month high of $45.00. The company has a quick ratio of 6.22, a current ratio of 6.54 and a debt-to-equity ratio of 0.25. The company has a 50-day simple moving average of $40.85 and a two-hundred day simple moving average of $35.29. The stock has a market capitalization of $4.97 billion, a price-to-earnings ratio of -1,491.84 and a beta of 0.68.
NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, October 27th. The medical research company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. The firm had revenue of $125.40 million for the quarter, compared to analyst estimates of $126.23 million. During the same period last year, the firm earned $0.07 EPS. The business’s quarterly revenue was up 19.8% compared to the same quarter last year.
In other NeoGenomics news, Director Bruce K. Crowther sold 8,333 shares of the firm’s stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $35.01, for a total value of $291,738.33. Following the transaction, the director now directly owns 46,483 shares of the company’s stock, valued at approximately $1,627,369.83. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Oort Douglas M. Van sold 340,000 shares of the firm’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $42.01, for a total transaction of $14,283,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,384,038 shares in the company, valued at $100,153,436.38. The disclosure for this sale can be found here. Over the last three months, insiders sold 797,902 shares of company stock worth $31,665,001. Insiders own 6.50% of the company’s stock.
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Further Reading: What is the Difference Between Common Shares and Convertible Shares?
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.